Hubbard J - Search Results

1

The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials.

Sonbol MB, Mountjoy LJ, Firwana B, Liu AJ, Almader-Douglas D, Mody K, Hubbard J, Borad M, Ahn DH, Murad MH, Bekaii-Saab T. Sonbol MB, et al. Among authors: hubbard j. JAMA Oncol. 2020 Mar 1;6(3):e194489. doi: 10.1001/jamaoncol.2019.4489. Epub 2020 Mar 12. JAMA Oncol. 2020. PMID: 31855256 Free PMC article.

2

Antiangiogenesis agents in colorectal cancer.

Hubbard J, Grothey A. Hubbard J, et al. Curr Opin Oncol. 2010 Jul;22(4):374-80. doi: 10.1097/CCO.0b013e328339524e. Curr Opin Oncol. 2010. PMID: 20375894 Review.

3

Treatment of liver-limited metastatic colorectal cancer.

Hubbard JM, Alberts SR. Hubbard JM, et al. Cancer J. 2010 May-Jun;16(3):235-40. doi: 10.1097/PPO.0b013e3181e075e9. Cancer J. 2010. PMID: 20526102 Review.

4

Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set.

Hubbard J, Thomas DM, Yothers G, Green E, Blanke C, O'Connell MJ, Labianca R, Shi Q, Bleyer A, de Gramont A, Sargent D. Hubbard J, et al. J Clin Oncol. 2012 Jul 1;30(19):2334-9. doi: 10.1200/JCO.2011.41.1975. Epub 2012 May 21. J Clin Oncol. 2012. PMID: 22614981 Free PMC article.

5

Adolescent and young adult colorectal cancer.

Hubbard JM, Grothey A. Hubbard JM, et al. J Natl Compr Canc Netw. 2013 Oct 1;11(10):1219-25. doi: 10.6004/jnccn.2013.0144. J Natl Compr Canc Netw. 2013. PMID: 24142823 Review.

6

Colorectal cancer in 2014: progress in defining first-line and maintenance therapies.

Hubbard JM, Grothey A. Hubbard JM, et al. Nat Rev Clin Oncol. 2015 Feb;12(2):73-4. doi: 10.1038/nrclinonc.2014.233. Epub 2015 Jan 6. Nat Rev Clin Oncol. 2015. PMID: 25560533 Review.

7

Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers.

Kasi PM, Hubbard JM, Grothey A. Kasi PM, et al. Expert Rev Gastroenterol Hepatol. 2015 Mar;9(3):273-6. doi: 10.1586/17474124.2015.1001743. Epub 2015 Jan 12. Expert Rev Gastroenterol Hepatol. 2015. PMID: 25579664 Review.

8

When less is more: maintenance therapy in colorectal cancer.

Hubbard JM, Grothey A. Hubbard JM, et al. Lancet. 2015 May 9;385(9980):1808-10. doi: 10.1016/S0140-6736(14)62350-3. Epub 2015 Apr 7. Lancet. 2015. PMID: 25862518 No abstract available.

9

Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.

Hubbard JM, Kim G, Borad MJ, Johnson E, Qin R, Lensing J, Puttabasavaiah S, Wright J, Erlichman C, Grothey A. Hubbard JM, et al. Invest New Drugs. 2016 Feb;34(1):96-103. doi: 10.1007/s10637-015-0308-5. Epub 2015 Nov 18. Invest New Drugs. 2016. PMID: 26581401 Free PMC article. Clinical Trial.

10

Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance).

Hubbard JM, Mahoney MR, Loui WS, Roberts LR, Smyrk TC, Gatalica Z, Borad M, Kumar S, Alberts SR. Hubbard JM, et al. Target Oncol. 2017 Apr;12(2):201-209. doi: 10.1007/s11523-016-0467-0. Target Oncol. 2017. PMID: 27943153 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,145 results

Search Page